GLP-1 & compounded medication availability in Maine (2026)
Maine sits at the quiet end of the spectrum: its pharmacy framework works through annual licensure, including a license classification that exists precisely for pharmacies shipping into the state by mail, rather than through medication-specific pronouncements. Eight of the ten product lines we track ship to Maine addresses today, and the two that do not are listed just as plainly as the eight that do.
What ships to Maine, line by line
| Product line | Available in Maine? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Ships from partner pharmacies holding Maine’s mail-order license classification. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same flat national price at every dose level. |
| NAD+ | Yes | 8–10 business days | Ordered through the standard telehealth flow. |
| Sermorelin | Yes | 8–10 business days | Fulfilled by licensed partner pharmacies. |
| Glutathione | No | N/A | Not in the OrderlyMeds catalog yet, an honest gap. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; its cited federal record is below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable; see its own section below. |
| KPV | No | N/A | Not carried in any state, since our peptide lines are injectables only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal facts below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; its federal record below is distinct from its siblings’. |
Facts last reviewed November 16, 2026. A No in this table is information, not a placeholder. If a line joins the Maine catalog, the row changes and the date moves with it.
The five research peptides, answered for Maine
Maine follows the national pattern: BPC-157, TB-500, Epitalon and MOTS-c are in the OrderlyMeds formulary as compounded injectables, KPV is not in it anywhere, and none of that changes at the state line. What deserves your attention is the cited federal record inside each section, FDA’s safety position and the current compounding pathway for that exact substance, stated once for each of the five, on identical terms whether the row above says Yes or No.
BPC-157 in Maine
Maine orders for BPC-157 are dispensed as a compounded injectable, on a patient-specific prescription.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Maine
TB-500 ships to Maine addresses in compounded injectable form, on a patient-specific prescription.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Maine
KPV is not in the OrderlyMeds catalog for Maine or anywhere else, because our peptide lines are injectables and KPV is not one.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Maine
Epitalon is dispensed to Maine as a compounded injectable.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Maine
MOTS-c ships to Maine as a compounded injectable; the federal record below is its own, not a copy of its siblings’.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Maine’s pharmacy regulators say about compounded medications
Maine’s approach is licensure all the way down. The state’s pharmacy framework, administered by a board inside the Department of Professional and Financial Regulation, sorts pharmacies into license classifications and attaches its requirements to the license rather than to individual medications. One of those classifications exists for exactly the situation this page describes: an out-of-state pharmacy dispensing to a Maine patient by mail or carrier.
Maine licenses pharmacies, including those that compound, under the Maine Pharmacy Act (32 M.R.S. ch. 117); the board has published no GLP-1-specific or peptide-specific restriction. Source: Maine Pharmacy Act, 32 M.R.S. ch. 117.
A pharmacy that dispenses prescription medication by mail or carrier from outside Maine to a patient in Maine must obtain an annual license from the board in the mail order prescription pharmacy classification (32 M.R.S. §13751). Source: 32 M.R.S. §13751 — Registration.
Maine permits prescribing on the basis of a telehealth encounter: licensees providing telehealth services are held to the same standards of practice that govern in-person care (32 M.R.S. §3300-DD), and no in-person-first requirement applies to the medications on this page. Sources: 32 M.R.S. §3300-DD — Professional responsibility · CCHP Policy Finder.
For a patient in Portland or Bangor the order flow is the standard one: an online eligibility check, a telehealth evaluation with a provider authorized for Maine, fulfillment by a partner pharmacy holding the state’s mail-order license classification, and tracked delivery inside the published 8–10 business-day window. Pricing is national, so the Maine price is the published price, at every dose.
Maine availability FAQs
Does OrderlyMeds ship compounded semaglutide to Maine?
Yes. Compounded semaglutide and compounded tirzepatide both ship to Maine addresses, from $74/month for new semaglutide customers in their first two months.
Do Maine patients need an in-person doctor visit first?
No. A telehealth evaluation by a provider authorized for Maine is the standard OrderlyMeds flow; the regulator section above cites the state’s telehealth standards.
Which research peptides ship to Maine?
BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable on a patient-specific prescription. KPV does not ship anywhere, because it is not an injectable line. Each section above cites that substance’s own federal record.
How long does delivery to Maine take?
The published window is 8–10 business days from signup, with tracking the whole way.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
